Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Patient-derived Xenograft
100%
Preclinical Testing
75%
Osteosarcoma
75%
Clinical Trials
15%
Eribulin
15%
Clinical Trial Development
10%
Drug Action
7%
Brentuximab Vedotin
7%
Cyclophosphamide
7%
ALK Inhibitor
7%
Patient Survival
7%
Rapamycin
7%
Etoposide
7%
Cisplatin
7%
Insulin-like Growth Factor 1 Receptor (IGF1R)
7%
Novel Treatments
7%
Eltrombopag
7%
Genetic Changes
7%
Novel Agents
7%
Tumor
7%
Testing Program
7%
Pediatric
7%
In Vitro Data
7%
Children's Oncology Group
7%
Inhibitory Activity
7%
Medicine and Dentistry
Xenograft
100%
Osteosarcoma
100%
Clinical Trial
30%
Eribulin
20%
Disease
20%
Cisplatin
10%
Oncology
10%
In Vitro
10%
Neoplasm
10%
Glembatumumab Vedotin
10%
Pediatrics
10%
Rapamycin
10%
Gene Mutation
10%
Cyclophosphamide
10%
Etoposide
10%
Drug Activity
10%
ALK Inhibitor
10%
Eltrombopag
10%
Pharmacology, Toxicology and Pharmaceutical Science
Osteosarcoma
75%
Clinical Trial
22%
Disease
15%
Eribulin
15%
Anaplastic Lymphoma Kinase Inhibitor
10%
Glembatumumab Vedotin
10%
Neoplasm
7%
Eltrombopag
7%
Rapamycin
7%
Cyclophosphamide
7%
Etoposide
7%
Cisplatin
7%